Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET
Company Participants
AJ Bergmann - CFO
Linda Marbán - CEO
Conference Call Participants
Alan Leong - BioWatch News
Aydin Huseynov - Ladenburg
Brian Corday - BullBear Partners
Operator
Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics Incorporated Third Quarter 2022 Earnings Call. Today's conference is being recorded.
At this time, I'd like to turn the conference over to Mr. AJ Bergmann, Capricor Chief Financial Officer. Please go ahead.
AJ Bergmann
Thank you, and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential milestone payments and our possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions and expectations that are subject to change, involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports.
You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
With that, I'll turn the call over to Linda Marbán, CEO.
Linda Marbán
Good afternoon, and thank you for joining us for our third quarter 2022 conference call. Today, I will provide updates on our Duchenne muscular dystrophy program and our exosome platform as well as outline our priorities moving into 2023.
Starting first with our cell therapy, CAP-1002, for the treatment of DMD. As a reminder, CAP-1002 is comprised of allogeneic cardiosphere-derived cells, or CDCs. CAP-1002 is not made up of stem cells, but rather as a stromal cell line that is an endogenous population of cells derived from cardiac tissue that are then expanded using proprietary methods into multiple doses of 150 million cells.
Our current program for CAP-1002 is aimed at patients with advanced Duchenne muscular dystrophy for whom very few therapeutic options exist. This patient group is made up of about half of the DMD population or about 10,000 boys and young men in the United States. From a portfolio management perspective, we believe that should CAP-1002 be approved for this patient population, we would prioritize and consider expanding into younger patients with DMD and as well as exploring other similar neuromuscular diseases.